Paul Brown, Radiation Oncologist at Mayo Clinic, shared a post on LinkedIn about a paper by published in The Lancet Oncology:
“Final Update: CATNON non co-deleted anaplastic glioma
No benefit of concurrent temozolomide
Standard of Care after surgery Gr3 IDHm Astrocytoma→RT followed by 12 cycles TMZ.”
Title: Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Authors: Martin J. van den Bent, Santoesha A. Ghisai, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Paul M. Clement, Sara C. Erridge, Michael A. Vogelbaum, Anna K. Nowak, Jean-François Baurain, Warren P. Mason, Helen Wheeler, Emeline Tabouret, Sanjeev Gill, Matthew Griffin, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Jaap C. Reijneveld, Roelien H. Enting, Sébastien Tran, Thierry Lesimple, Martin Kocher, Anja Gijtenbeek, Elizabeth Lim, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Kenneth Aldape, Robert B. Jenkins, Hendrikus Jan Dubbink, Johan M. Kros, Pieter Wesseling, Youri Hoogstrate, Sarah Nuyens, Vassilis Golfinopoulos, C. Mircea S. Tesileanu, Thierry Gorlia, Pim French, and Brigitta G. Baumert.
You can read the Full Article in The Lancet Oncology.
More posts featuring Paul Brown.
